We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+4.97%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$83.2B
AUM Growth
+$1.08B
Cap. Flow
-$819M
Cap. Flow %
-0.99%
Top 10 Hldgs %
34.54%
Holding
3,151
New
709
Increased
920
Reduced
837
Closed
626

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$1.06B
2
UNH icon
UnitedHealth
UNH
+$935M
3
UBER icon
Uber
UBER
+$426M
4
BA icon
Boeing
BA
+$312M
5
CRM icon
Salesforce
CRM
+$309M

Sector Composition

Rank Sector Weight
1 Technology 20.14%
2 Consumer Discretionary 14.92%
3 Healthcare 12.54%
4 Financials 8.46%
5 Industrials 6.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KBDC
2201
Kayne Anderson BDC
KBDC
$903M
$300K ﹤0.01%
18,117
+4,359
+32% +$71.6K
SMID icon
2202
Smith-Midland
SMID
$164M
$300K ﹤0.01%
+6,738
New +$268K
BY icon
2203
Byline Bancorp
BY
$1.76B
$299K ﹤0.01%
+10,327
New +$299K
MSI icon
2204
Motorola Solutions
MSI
$70.3B
$299K ﹤0.01%
647
-33,964
-98% -$16.1M
APOG icon
2205
Apogee Enterprises
APOG
$855M
$299K ﹤0.01%
+4,183
New +$328K
MTAL
2206
DELISTED
Metals Acquisition
MTAL
$297K ﹤0.01%
+28,011
New +$346K
CIBR icon
2207
First Trust NASDAQ Cybersecurity ETF
CIBR
$14B
$295K ﹤0.01%
4,643
-7,804
-63% -$490K
TCHP icon
2208
T. Rowe Price Blue Chip Growth ETF
TCHP
$2.07B
$295K ﹤0.01%
6,995
-4,744
-40% -$197K
FDMT icon
2209
4D Molecular Therapeutics
FDMT
$543M
$294K ﹤0.01%
52,744
-112,449
-68% -$882K
RYAAY icon
2210
Ryanair
RYAAY
$29.8B
$292K ﹤0.01%
6,689
-46,606
-87% -$2.08M
ASPN icon
2211
Aspen Aerogels
ASPN
$385M
$291K ﹤0.01%
24,530
-6,570
-21% -$112K
LGF.B
2212
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
$289K ﹤0.01%
38,269
-214,880
-85% -$1.51M
ENPH icon
2213
Enphase Energy
ENPH
$5.01B
$288K ﹤0.01%
4,200
-45,467
-92% -$3.61M
GCBC icon
2214
Greene County Bancorp
GCBC
$569M
$286K ﹤0.01%
+10,321
New +$312K
ABEO icon
2215
Abeona Therapeutics
ABEO
$349M
$286K ﹤0.01%
51,328
-32,846
-39% -$202K
ADAP
2216
DELISTED
Adaptimmune Therapeutics
ADAP
$286K ﹤0.01%
529,123
+6,515
+1% +$4.75K
PGY icon
2217
Pagaya Technologies
PGY
$1.41B
$283K ﹤0.01%
30,424
-598,424
-95% -$6.32M
MUX icon
2218
McEwen Inc
MUX
$1.04B
$281K ﹤0.01%
36,085
-4,895
-12% -$44.2K
NWPX icon
2219
NWPX Infrastructure Inc
NWPX
$1.24B
$279K ﹤0.01%
5,772
-2,138
-27% -$107K
KFY icon
2220
Korn Ferry
KFY
$4.13B
$278K ﹤0.01%
+4,128
New +$300K
CTOS icon
2221
Custom Truck One Source
CTOS
$2.44B
$278K ﹤0.01%
+57,843
New +$262K
HUMA icon
2222
Humacyte
HUMA
$182M
$277K ﹤0.01%
54,917
-529,645
-91% -$2.62M
FOA icon
2223
Finance of America Companies
FOA
$211M
$277K ﹤0.01%
+9,844
New +$175K
KYMR icon
2224
Kymera Therapeutics
KYMR
$9.05B
$275K ﹤0.01%
6,835
-110,846
-94% -$5.01M
COST icon
2225
PUT
Costco
COST
$422B
$275K ﹤0.01%
300
-3,100
-91% -$2.88M

Similar funds

Marshall Wace's Q4 2024 Portfolio in Review

As of Q4 2024, Marshall Wace held 3,151 positions worth $83.2B, up 1.3% from $82.1B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Marshall Wace's Q4 2024 filing shows 709 new, 920 increased, 837 reduced and 626 closed positions. Its largest new stake was Boeing: 1,988,038 shares worth $352M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.09B.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Marshall Wace's largest Q4 2024 buy was Boeing: 1,988,038 shares worth $352M.
  • Marshall Wace added most to Apple in Q4 2024, an estimated $1.06B increase.
  • Marshall Wace's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.09B.
  • Marshall Wace fully exited GE Vernova in Q4 2024, selling an estimated $439M.
  • Marshall Wace's ten largest holdings make up 35% of its $83.2B portfolio in Q4 2024.
  • Marshall Wace opened 709 new positions and closed 626 in Q4 2024.
  • Marshall Wace's portfolio value rose 1.3% quarter-over-quarter to $83.2B.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.